ROCKAWAY, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic technology company, announced today that it will report financial results for the first quarter ended March 31, 2025, after the close of the market on Wednesday, May 7, 2025.
Management will host a webinar at 4:30 PM EST to review the financial results and answer questions. Investors can access the webinar using the details below:
Wednesday, May 7, 4:30 PM EST
Dial-In: (646) 931-3860
Webinar ID: 885 4355 1292
Passcode: 419231
Registration Link: Click here to participate and ask questions on the call.
About electroCore, Inc.
electroCore, Inc. and its subsidiaries (“electroCore” or the “Company”) is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies.
For more information, visit www.electrocore.com.
Contact
ECOR Investor Relations
(973) 302-9253
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$6.91 |
| Daily Change: | 0.12 1.77 |
| Daily Volume: | 134,644 |
| Market Cap: | US$45.260M |
March 12, 2025 February 27, 2025 February 06, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
